ストックスクリーナーアプリを入手
10.94
0.09%
0.010
プレマーケット:
10.70
-0.24
-2.19%
Gossamer Bio Inc (GOSS) 最新ニュース
Gossamer Bio Inc (GOSS) Stock Price Target & Forecast - TradingKey
Form 4 Gossamer Bio Inc For: 25 September By Investing.com - Investing.com Nigeria
At $10.99 a share, Gossamer Bio (GOSS) director Sandra Milligan receives a stock option. - Stock Titan
At Gossamer Bio (GOSS), director Daniel Thomas O's options carry a $10.99 exercise price. - Stock Titan
Gossamer Bio (GOSS) grants a director options priced at $10.99 per share - Stock Titan
At Gossamer Bio (GOSS), director Drynan Skye receives stock options priced at $10.99 per share. - Stock Titan
Director Russell J. Cox receives Gossamer Bio (GOSS) options with a $10.99-per-share exercise price. - Stock Titan
Gossamer Bio grants director options on 10,000 shares - Stock Titan
Gossamer Bio stock falls 5.99 percent after FDA filing - AD HOC NEWS
Gossamer Bio submits seralutinib NDA after Phase 3 endpoint miss - mugglehead.com
Gossamer Bio Submits First NDA for Seralutinib to FDA for Pulmonary Arterial Hypertension - Kalkine Media
Gossamer Bio (GOSS) Files NDA for Seralutinib Amidst Challenging Valuation Landscape - GuruFocus
Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension - TradingView
Gossamer Bio stock rises on FDA filing for PAH drug - Investing.com India
Gossamer Bio Files New Drug Application for Seralutinib - Yahoo Finance
Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension - TradingView
Gossamer Bio stock rises on FDA filing for PAH drug By Investing.com - Investing.com Canada
Gossamer Bio submits NDA for seralutinib in PAH treatment By Investing.com - Investing.com Australia
Gossamer Bio (GOSS) Files NDA for Seralutinib Amid Low Valuation and Mixed Financial Signals - GuruFocus
Gossamer Bio submits NDA for seralutinib in PAH treatment - Investing.com
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension - Yahoo Finance
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Gossamer Bio stock gains 12.04 percent in the latest quote - AD HOC NEWS
Equity in earnings of Gossamer Bio, Inc. – SWB:4GB0 - TradingView
Total assets of Gossamer Bio, Inc. – SWB:4GB0 - TradingView
GOSS Maintained by HC Wainwright & Co. -- Price Target Raised to $90 - GuruFocus
GOSS Price Target Soars to $90 After Reverse Split; Market Prici - GuruFocus
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
HC Wainwright & Co. maintains Buy rating on Gossamer Bio, $90 price target - TradingView
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Cash flow from financing activities of Gossamer Bio, Inc. – MUN:4GB0 - TradingView
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio Adds Veteran Investor to Board of Directors - The Globe and Mail
Gossamer Bio (NASDAQ: GOSS) Schedules October 27 Vote on Warrants and Preferred Stock Conversion - kalkinemedia.com
Cash flow from financing activities of Gossamer Bio, Inc. – LSX:A42M0V - TradingView
Total assets of Gossamer Bio, Inc. – LSX:A42M0V - TradingView
Gossamer Bio appoints Greg Ciongoli to board of directors By Investing.com - Investing.com Nigeria
Gossamer Bio appoints Greg Ciongoli to board of directors - Investing.com
Gossamer Bio, Inc. Announces Appointment of Greg Ciongoli to Board of Directors and Audit Committee, Effective September 16, 2026 - marketscreener.com
Gossamer Bio Appoints Greg Ciongoli to Board of Directors - Yahoo Finance
Gossamer Bio Inc to discuss its business update Transcript - GuruFocus
Gossamer Bio Inc (FRA:4GB0) Stock Price & 30 Year Financial Data - GuruFocus
Gossamer Bio (FRA:4GB0) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2026) - GuruFocus
Gossamer Bio (FRA:4GB0) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2026) - GuruFocus
Gossamer Bio Inc (FRA:4GB0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 8K Gossamer Bio Inc For: 11 September By Investing.com - Investing.com Nigeria
Gossamer Bio completes 1-for-80 reverse stock split By Investing.com - Investing.com Australia
Gossamer Bio Implements 1-for-80 Reverse Stock Split to Address Nasdaq Compliance - citybiz
Gossamer Bio Executes Reverse Stock Split and Share Reduction - TipRanks
Gossamer Bio completes 1-for-80 reverse stock split - investing.com
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split - Business Wire
GOSS: Static price chart | Gossamer Bio | US38341P1021 - marketscreener.com
Gossamer Bio: Dividend historical data and projections - marketscreener.com
Gossamer Bio: Performance & Quotes, GOSS Stock Price on Nasdaq Exchange - marketscreener.com
Gossamer Bio completes 80-for-1 reverse stock s... - Pluang
Gossamer Bio Stock (GOSS)Quote Nasdaq - marketscreener.com
Gossamer Bio To Carry Out 1-for-80 Reverse Stock Split On September 11th, 2026 - Moomoo
Gossamer Bio at Cantor Fitzgerald healthcare conference: filing path in focus - Investing.com Canada
Gossamer Bio Announces 1-for-80 Reverse Stock Split - tipranks.com
Gossamer Bio announces 1-for-80 reverse stock split, authorized shares cut to 50M - TradingView
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):